Hyperphosphatemia - Pipeline Insight, 2024

This “Hyperphosphatemia - Pipeline Insight, 2024,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Hyperphosphatemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Hyperphosphatemia Understanding

Hyperphosphatemia: Overview

Hyperphosphatemia or even serum phosphate levels within the “normal laboratory range” are highly associated with increased cardiovascular disease risk and mortality in the general population and patients suffering from chronic kidney disease (CKD). As the kidney function declines, serum phosphate levels rise and subsequently induce the development of hypertension, vascular calcification, cardiac valvular calcification, atherosclerosis, left ventricular hypertrophy and myocardial fibrosis by distinct mechanisms. Therefore, phosphate is considered as a promising therapeutic target to improve the cardiovascular outcome in CKD patients. The current therapeutic strategies are based on dietary and pharmacological reduction of serum phosphate levels to prevent hyperphosphatemia in CKD patients.

Hyperphosphatemia - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hyperphosphatemia pipeline landscape is provided which includes the disease overview and Hyperphosphatemia treatment guidelines. The assessment part of the report embraces, in depth Hyperphosphatemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hyperphosphatemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Hyperphosphatemia R&D. The therapies under development are focused on novel approaches to treat/improve Hyperphosphatemia.

Hyperphosphatemia Emerging Drugs Chapters

This segment of the Hyperphosphatemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Hyperphosphatemia Emerging Drugs

FC818 (ferric citrate): PUMC PharmaceuticalFC818 is a novel non-calcium-based phosphate binder. One Phase I and two pivotal Phase II clinical trials showed FC818 to be an effective and safe treatment for lowering and/or maintaining serum phosphorus levels < 5.5 mg/dL in ESRD patients with hyperphosphatemia. The drug is currently in Phase III stage of clinical trial evaluation to treat Hyperphosphataemia.

VS 505: Shanghai Alebund PharmaceuticalsVS 505 is a phosphate binding modulator being developed by Shanghai Alebund Pharmaceuticals for the treatment of Hyperphosphataemia.. The drug is currently in Phase II stage of clinical trial evaluation to treat Hyperphosphataemia.

Hyperphosphatemia: Therapeutic Assessment

This segment of the report provides insights about the different Hyperphosphatemia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Hyperphosphatemia

There are approx. 15+ key companies which are developing the therapies for Hyperphosphatemia. The companies which have their Hyperphosphatemia drug candidates in the most advanced stage, i.e. phase III include, PUMC Pharmaceutical.

Phases

This report covers around 15+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Hyperphosphatemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hyperphosphatemia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hyperphosphatemia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hyperphosphatemia drugs.

Hyperphosphatemia Report Insights

• Hyperphosphatemia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Hyperphosphatemia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Hyperphosphatemia drugs?
• How many Hyperphosphatemia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hyperphosphatemia?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Hyperphosphatemia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Hyperphosphatemia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• PUMC Pharmaceutical
• Shanghai Alebund Pharmaceuticals
• Ardelyx
• Kyowa Kirin
• Phosphate Therapeutics
• Liaoning Grand Nuokang Biopharmaceutical Co., Ltd.
• Chugai Pharmaceutical
• Keryx Biopharmaceuticals
• Panion & BF Biotech Inc.
• Sinomune Pharmaceutical
• Daiichi Sankyo
• J-Pharma
• OPKO Renal
• Altair Nanotechnologies
• China Nuokang Bio-Pharmaceutical
• Unicycive Therapeutics

Key Products

• FC818 (ferric citrate)
• VS 505
• Tenapanor
• PT20
• EOS789
• DS-2330b
• JPH 101
• Fermagate
• Lanthanum dioxycarbonate
• Lanthanum polystyrene sulfonic acid

This product will be delivered within 1-3 business days.